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Abstract
Introduction Recombinant activated factor VII (rFVIIa) has been
used as adjunctive therapy in trauma patients with severe
bleeding. However, its pharmacokinetics profile remains
unknown.
Methods In two placebo-controlled studies in patients with
blunt and penetrating trauma, the pharmacokinetics of rFVIIa
given at an initial dose of 200 µg.kg-1 after transfusion of eight
red blood cell units, followed by additional doses of 100 µg.kg-
1, one and three hours later, have been studied, based on the
FVII coagulant activity assay. Both non-compartment and
population pharmacokinetic analyses were performed. A two-
compartment, population pharmacokinetic model was used to
estimate a population profile for the rFVIIa dosing regimen. Data
are population means (percent coefficient of variation (CV)).
Results Based on the two-compartment population model, the
estimated pharmacokinetic parameters were: clearance 40
(30% CV) ml.kg-1.h-1; central volume of distribution 89 (32%
CV) ml.kg-1; inter-compartmental clearance 24 ml.kg-1.h-1; and
peripheral compartment volume 31 ml.kg-1. Baseline FVII
coagulant activity was estimated at 0.29 (39% CV) U.ml-1, initial
half-life was 0.6 (34% CV) hours, and terminal half-life 2.4 (50%
CV) hours. High intra- and inter-patient variability was noted in
volume of distribution and clearance, which was in part
correlated with the transfusion requirements as the single
significant covariate. The non-compartmental analysis led to
almost identical estimates of key parameters.
Conclusion A high intra- and inter-patient variability was noted
in the volume of distribution and clearance of rFVIIa in trauma
patients with severe bleeding, mainly related with the transfusion
requirements and thus blood loss and/or bleeding rate.
Introduction
Recombinant activated factor VII (rFVIIa, NovoSeven®/Nia-
stase®, Novo Nordisk A/S, Bagsvaerd, Denmark) is an effec-
tive first-line hemostatic agent for the management of acute
and surgical bleeds in patients with hemophilia A or B and
inhibitors to factor VIII or factor IX [1]. The ability of rFVIIa to
provide effective hemostasis in patients with a variety of clini-
cal conditions associated with bleeding can be attributed to its
capacity to increase thrombin generation on the surface of
activated platelets accumulated at the site of injury to the ves-Page 1 of 10
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AUC = area under the curve; Cmax = maximum concentration; CV = coefficient of variation; RBC = red blood cell; rFVIIa = recombinant factor VIIa; 
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Critical Care    Vol 10 No 4    Klitgaard et al.sel wall, and, by directly activating factor X in the absence of
tissue factor, this agent promotes the formation of a tight, sta-
ble fibrin plug at the site of injury [2,3]. An expanding literature
suggests that rFVIIa has the potential for broad-spectrum
applications in situations characterized by profuse bleeding
and impaired thrombin generation [4-6], including severe
trauma [7,8], although some other studies suggest that its pre-
ventive use in potentially bleeding situations may not be appro-
priate [9].
A randomized study in trauma patients recently demonstrated
that adjunctive therapy with rFVIIa controls bleeding, resulting
in a significant reduction in red blood cell (RBC) transfusion
requirements and in the occurrence of massive transfusion
[10]. In the trauma population it is difficult to measure the
amount of blood loss accurately. Accordingly, units of RBC
transfused was chosen as a surrogate endpoint for bleeding,
and units of RBC transfused during the 48 hour observation
period following the initial dose of trial product was chosen as
the primary endpoint to indicate the ability of rFVIIa to control
bleeding [10]. Among the patients with blunt trauma and sur-
viving the initial 48 hours after first dose, RBC transfusion was
significantly reduced with rFVIIa relative to placebo (estimated
reduction of 2.6 RBC units, P = 0.02), and the need for mas-
sive transfusion (>20 RBC), a post hoc analysis, was also sig-
nificantly reduced (14% versus 33% of patients, P = 0.03). In
penetrating trauma, similar analyses showed trends towards
rFVIIa reducing RBC transfusion (estimated reduction of 1.0
RBC units, P = 0.10), and massive transfusion (7% versus
19% of patients, P = 0.08) [10].
Clinical studies have not identified pharmacodynamic markers
that can reliably predict the in vivo hemostatic effect of rFVIIa.
Instead, dose selection is guided by in vitro studies with
human biomaterials, clinical experience, among other from
studies in patients with hemophilia [3,11-14], and an under-
standing of the time course of the drug levels with dose, that
is, the pharmacokinetics.
The objectives of our study were to address the latter issue,
using two different analytical approaches to describe the phar-
macokinetic profile of rFVIIa in trauma patients with severe
bleeding. Moreover, our aim was also to identify significant and
clinically relevant covariates affecting pharmacokinetics in this
population. The present study is an ancillary pharmacokinetic
study of the large clinical trial that has been recently published
[10].
Materials and methods
The study protocol was approved by the ethics committee of
each participating institution, and the trial was conducted
according to Good Clinical Practice standards and the Hel-
sinki Declaration. Written, informed consent was obtained
from all patients, or, where applicable, from a legally authorized
representative. Due to the emergency conditions and the pos-
sible absence of relatives at enrolment into the trial, waived
informed consent was authorized by the ethical committees.
However, whenever a patient was included without written
informed consent, such consent was promptly searched from
a legally authorized representative and subsequently from the
patient himself. When adequate confirmation of consent was
not obtained, data were excluded from analysis.
The methods of the study have been previously detailed [10].
Briefly, to be eligible for inclusion, patients were to have
received six units of RBC within a four-hour period, and to be
of known age = 16 years (or legally of age according to local
law) and <65 years. Key exclusion criteria comprised: cardiac
arrest pre-hospital or in the emergency or operating room prior
to trial drug administration; gunshot wound to the head; Glas-
gow coma scale <8 unless in the presence of a normal head
CT scan; base deficit of >15 mEq.l-1 or severe acidosis with
pH <7.00; transfusion of eight units or more of RBC prior to
arrival at trauma center; and injury sustained = 12 hours before
randomization.
This was a randomized, placebo-controlled, double-blind trial
with two parallel treatment arms in two separate trauma popu-
lations. Patients were evaluated for inclusion into the trial on
admission to the trauma center, and eligible patients were
assigned to either the blunt or penetrating trauma trial arm.
Upon receiving six units of RBC within a four-hour period, eli-
gible patients within each trauma population were equally ran-
domized to receive either three intravenous injections of rFVIIa
(200, 100 and 100 µg.kg-1) or three placebo injections. The
first dose of trial product was to be administered immediately
after transfusion of the eighth unit of RBC, given that the
patient, in the opinion of the attending physician, would require
additional transfusions. The second and third doses followed
one and three hours after the first dose, respectively. This dose
regimen was chosen to target an average concentration of
FVIIa >40 U.ml-1, based on in vitro studies and clinical studies
conducted in hemophilic patients. Trial product was adminis-
tered in addition to standard treatment for injuries and bleed-
ing at the participating hospitals, and no restrictions were
imposed on procedures deemed necessary by the attending
physician, including surgical interventions, resuscitation strat-
egies, and use of blood products. However, before patient
enrolment, each participating trauma center developed spe-
cific transfusion guidelines in line with the transfusion guide-
lines provided in the study protocol.
FVII coagulant activity assay
All pharmacokinetic assessments in this study were based on
the FVII coagulant activity assay, a one-stage clotting assay
using thromboplastin tissue factor, which forms complexes
with both FVIIa and FVII zymogen to quantify FVII clotting activ-
ity in plasma (Capio Diagnostik A/S, Copenhagen, Denmark)
[15]. The lower limit of quantification for the assay is 0.06 U.ml-
1. The assay involves use of diluted samples of plasma thatPage 2 of 10
(page number not for citation purposes)
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then adjusted to 37°C, and coagulation was initiated by the
addition of thromboplastin tissue factor and calcium chloride.
The time until fibrin formation was measured and related to the
time observed for this reaction in normal plasma. Due to the
temperature adjustment and the sample dilution in buffer and
FVII-deficient plasma (which has a high buffer capacity), no
effect of hypothermia or acidosis on assay results are
expected. Since the FVII coagulant activity assay does not dis-
tinguish endogenous FVII/FVIIa from rFVIIa, baseline plasma
activity (that is to say, before administration of rFVIIa) was
taken into account in the pharmacokinetic analyses. The ther-
apeutic doses of rFVIIa used in the study were expected to
give peak plasma concentrations at least 30-fold greater than
the normal endogenous FVII/FVIIa level in non-coagulopathic
patients.
Pharmacokinetic sampling
Within the two study populations of blunt and penetrating
trauma, subjects were allocated to two groups for pharmacok-
inetic analysis, one group to frequent blood sampling and
another to sparse blood sampling for determination of FVII
coagulant activity assay. The frequent sampling group com-
prised approximately 50 patients from whom plasma was sam-
pled before first dose of trial product and 30 minutes and 1, 2,
3, 4, 6, 8 and 12 hours after the first dose. The remaining
patients formed the sparse sampling group, from whom one
sample was taken in each of at least two of the following four
time intervals: 0 to 1 hour (after the first dose but before the
second dose); 1 to 3 hours (after the second dose but before
the third dose); 3 to 8 hours (after the third dose); and 8 to 12
hours.
Pharmacokinetic analyses
Data from patients with frequent sampling were analyzed non-
compartmentally, whereas data from both patients with fre-
quent and patients with sparse sampling were used for popu-
lation pharmacokinetic analysis. The latter approach –
population analysis – is suitable for this type of data. In con-
trast to the non-compartmental analysis – which is based upon
separate analysis of each individual profile and requires that
enough data be available for each individual to actually esti-
mate the individual pharmacokinetics profiles – the population
approach does not have this constraint. Instead, even very
sparsely sampled individual profiles can be included in the
dataset, in addition to the more richly sampled profiles. Even-
tually, an overall 'population pharmacokinetic profile' is esti-
mated, as are estimates of how the parameters describing this
profile vary between individuals. Using this approach, the
effect of a number of covariates on individual parameters may
also be analyzed [16,17].
As mentioned, the FVIIa coagulant assay does not distinguish
endogenous FVII/FVIIa from rFVIIa. Although very small in
comparison with the levels obtained during FVIIa treatment, a
baseline FVIIa coagulant activity level was estimated for each
individual and adjusted for in the analysis. In the non-compart-
mental analysis, the level was estimated based on pre-dose
FVIIa coagulant activity levels and subtracted from the post-
dose measurements; in the population analysis, the level was
included as a subject specific random effect and estimated as
part of the model estimation procedure. The mean baseline
level was estimated at 0.30 and 0.29 U.ml-1 for the placebo
and the treatment group, respectively (non-compartmental
estimates).
Non-compartmental analysis
The following parameters were estimated: maximum plasma
FVII coagulant activity from time of first dose (time zero) to 12
hours after first dose (Cmax); time to maximum plasma FVII
coagulant activity (Tmax); area under the plasma FVII coagulant
activity-time profile from time of first dose (time zero) to 12
hours after first dose (AUC0–12h); and volume of distribution
and clearance. For calculation of AUC0–12h, adjusted activities
below zero were substituted by zero.
Population analysis
In this analysis, both a one- and a two-compartment population
model were explored. Since the latter type was found to better
describe the data, the final model was a two-compartment
population model with first order elimination from the central
compartment and baseline FVII coagulant activity assay to
account for endogenous production of FVIIa. The influence of
the covariates RBC transfusion, body weight, type of injury
(blunt or penetrating), injury severity score, sex, age, and eth-
nicity on the model parameters were tested during develop-
ment of the model. These covariates, based on the available
data, were a priori identified as clinically relevant in collabora-
tion with the medical team. Results were compared to popula-
tion analysis results obtained in a previous study in hemophilia
patients (Novo Nordisk data on file). In this analysis, pharma-
cokinetic data previously analyzed non-compartmentally [18]
were analyzed with a two-compartment population pharma-
cokinetic model similar to the one presented here to allow for
simulation of the population pharmacokinetic profile in hemo-
philia patients.
The final population pharmacokinetic model was used to sim-
ulate the predicted mean profile for the trauma population, at
different levels of post-dose RBC transfusion requirements, as
clearance was found to correlate with this covariate.
Statistical analysis
Data are expressed as geometric and population means (non-
compartmental and population analysis, respectively), percent
coefficient of variation (%CV = standard deviation × 100/
mean) for pharmacokinetic parameters and arithmetic mean ±
standard deviation for other variables. All statistical compari-
sons were based on analysis of variance methods, using two-
tailed tests and a significance level of 0.05.Page 3 of 10
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statistical analysis was performed with SAS version 8.2 (SAS
Institute Inc., Cary, NC, USA). For the population pharmacoki-
netic analysis, data file preparation was performed with SAS
Version 8.2 and S-PLUS v. 6.0 for Trial Simulator (Insightful
Corporation, Seattle, WA, USA); non-linear mixed effects
modeling was performed with NONMEM version 5.11
(GoboMax, Hanover, MD, USA), run under Visual-NM Version
5.1 (RDPP, Montpellier, France). Visual Fortran Version 6.1
(Hewlet-Packard Company, Palo Alto, CA, USA) was used for
compiling and clinical trial simulation was performed with the
Pharsight Trial Simulator v. 2.1.2 (Pharsight Corporation,
Mountain View, CA, USA). Software was installed according
to vendor instructions. In addition, NONMEM functionality was
verified with a test script executed before modeling.
NONMEM's first order conditional estimation method with
interaction was used for model development. Evaluation and
discrimination of intermediate models was based on standard
statistical theory that the change in objective function value is
approximately Chi-square distributed, with degrees of freedom
corresponding to the difference in number of parameters [19].
Covariates were included in a forward inclusion approach, if
reduction in objective function value was significant at a P
value of 0.05. Subsequently, covariates were excluded by
backwards elimination from the full model, if the associated
increase in objective function value was not significant at a P
value of 0.001. This method ensured inclusion of the relevant
covariates, and the latter highly conservative significance level
was employed to retain only the most essential covariates,
leading to a more robust model.
Between and within patient variability was estimated as part of
the model estimation procedure in NONMEM. The between-
patient variation of parameter estimates was based upon the
assumption of individual parameter estimates being log-nor-
mal distributed around a population mean and is based on the
inclusion of a random subject effect for the parameter. The
number of parameters in the model must be balanced with the
amount of data. Thus, to avoid over-parametrization of the final
model, a random effect was not included for the inter-compart-
mental clearance and peripheral compartment volume. For
these parameters, between patient variability is hence not
reported. Within patient variation was estimated from the log
normal distribution of individual observations around the indi-
vidually predicted pharmacokinetic profiles. Both were
expressed as %CV. Confidence intervals for the parameter
estimates were calculated on the log-scale, as estimates ±
1.96 standard deviation.
Results
A total of 301 patients were randomized in the two studies,
158 in the blunt trauma arm and 143 in the penetrating trauma
arm. Of these, 18 were withdrawn before administration of trial
product, and waived informed consent was not confirmed for
6 patients. Of the remaining 277 patients, the pharmacokinetic
profiles from a total of 47 patients were excluded from the
dataset for the following reasons: no recording of actual sam-
pling time (n = 15); no FVII coagulant activity recordings (n =
13); apparently artifactual pre-dose FVII coagulant activity lev-
els or other aberrant data values (n = 3); and lack of informa-
tion on potentially relevant covariates in the population model
(n = 16). There were no significant differences between
excluded and included patients in age, sex, Injury Severity
Score, RBC requirement and survival (data not shown), sug-
gesting that our analysis was not affected by patient exclusion
bias. In the final pharmacokinetic dataset of 230 patients, 107
had been treated with placebo while the remaining 123
patients had been treated with rFVIIa. The population was
characterized by the following characteristics: mean age was
32 ± 11 years; mean Injury Severity Score was 28 ± 13; there
were 191 (83%) men and 39 (17%) women; and there were
110 (48%) patients with blunt trauma and 120 (52%) patients
with penetrating trauma.
Before performing the actual pharmacokinetic analyses, the
baseline level of FVIIa activity was explored, by plotting the
activity versus time for the 107 subjects treated with placebo.
The level appeared to be relatively constant in time, with ran-
dom fluctuations around an average level of 0.3 U.ml-1 (range,
0.07 to 1.4 U.ml-1). Based on this, baseline levels were
assumed individual specific, but constant in time.
Non-compartmental analysis
The frequent sampling group, for which the non-compartmen-
tal pharmacokinetic analysis was performed, comprised 43
patients, of which 18 patients were treated with placebo and
25 patients were treated with rFVIIa. Analysis was performed
only on rFVIIa-treated patients with at least five plasma FVII
Figure 1
Factor VII (FVII) coagulant activity measurements in recombinant FVIIa-trea ed blunt (n = 6) and penetrating (n = 15) trauma patients
treated blunt (n = 6) and penetrating (n = 15) trauma patients. One 
outlier was excluded from the population pharmacokinetic model data 
set.Page 4 of 10
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and 15 penetrating trauma patients (Figure 1). Results of the
non-compartmental analysis are summarized in Table 1. No
significant differences were noted in key pharmacokinetic
parameters between patients with blunt and penetrating
trauma. The uncertainty of the estimates of Cmax, Tmax, and vol-
ume of distribution was rather high, in particular for the group
of patients with blunt trauma, which was not unexpected, since
only a few patients contributed to these. Mean FVII coagulant
activity (blunt and penetrating groups) are shown in Figure 2.
Population analysis
In this analysis, data from 230 patients with frequent sampling
and sparse sampling were used, of whom 123 were treated
with rFVIIa. Diagnostics plots for the final population pharma-
cokinetic model indicated an acceptable fit of the model to the
data, considering the amount of and variation in data (data not
shown). The parameter estimates for the final population phar-
macokinetics model are presented in Table 2. Population
mean parameters for central compartment volume of distribu-
tion, clearance, and baseline are estimated with good preci-
sion and with estimates of the between-patient variation.
Population mean parameters for inter-compartmental clear-
ance and peripheral compartment volume are estimated with
somewhat lower precision. For this latter set of parameters,
the data did not allow for the estimation of inter-individual var-
iation. Residual intra-individual variation was estimated at
32%.
For clearance, a significant part of the variation (P < 0.001)
was attributable to differences in RBC transfusion require-
ments of the patients (Figure 2). Consequently, this clinically
relevant correlation was included in the final model by the
equation:
CL = 40.45 × 1.014(RBC-8.7)
where CL is the clearance, RBC is the RBC requirement after
the first dose of rFVIIa and 8.7 is the average post-dose RBC
requirement of the trauma population, indicating that the clear-
ance increases with increasing RBC transfusion requirement.
Application of the model
The final model was used to simulate the population pharma-
cokinetics profile (Figure 3). The observed data were found to
be quite variable. Nevertheless, most patients, based on data
from the trauma population and the estimated population phar-
macokinetics profile, achieved FVII coagulant activity at least
equal to or above the pharmacokinetics profile reached in
hemophilia patient populations given a single dose of 90
µg.kg-1. Within the first four hours after the first dose, only a
few patients (n = 10, 12%) had plasma concentrations below
the hemophilia profile (Figure 3), and 30 (75%), 40 (63%), and
32 (54%) patients achieved rFVIIa plasma concentrations
Table 1
Pharmacokinetic parameters of factor VII coagulant activity assessed by non-compartmental analysis in blunt and penetrating 
trauma patients with frequent sampling
Blunt (n = 6) Penetrating (n = 15)
Cmax (U.ml-1) 81 (47–241) [76%] 58 (41–102) [27%]
Tmax (h) 0.9 (0.5–4.0) [110%] 1.2 (0.5–4.0) [86%]
AUC0–12h (U.h.ml-1) 305 (216–362) [17%] 311 [182–520] [26%]
Clearance (ml.kg-1.h-1) 41 (34–58) [21%] 40 (25–79) [30%]
Volume of distribution (ml.kg-1) 83 (28–143) [45%] 112 (66–165) [24%]
Data are geometric means (min-max) and coefficient of variation [%]. There is no significant difference between the two groups. AUC0–12h, area 
under the plasma concentration-time profile from time of first dose (time zero) to 12 hours after first dose; Cmax, maximum plasma concentration; 
Tmax, time to maximum plasma concentration.
Figure 2
Correlation between clearance and red blood cell (RBC) transfusion requireme t af er first dose of recombinant factor VIIa (rFVIIa)
requirement after first dose of recombinant factor VIIa (rFVIIa). Plot of 
model-estimated, individual clearance versus measured post-dose 
RBC requirement (n= 123). R-squared value reflects the fraction of the 
variation in individual predicted clearance values explained by the 
model. P value reflects the significance level at which the hypothesis of 
no effect of RBC transfusion need after rFVIIa dosing on individual 
clearance was rejected. Dotted lines indicate 95% confidence interval 
of the regression curve.Page 5 of 10
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respectively.
As mentioned above, RBC transfusion requirement was the
single significant covariate in the model. To illustrate the
impact of this covariate, estimates of population clearance and
terminal half-life at various post-dose RBC requirements were
calculated. Increased RBC requirements were associated
with increased clearance, and consequently with shortening of
the terminal elimination half-life (Table 3). For comparison, esti-
mates of clearance and half-life for patients with hemophilia
are also presented. To further explore the effect of the covari-
ate, population profiles were simulated for various levels of
post-dose RBC transfusion requirements (Figure 4). Consist-
ent with the observed data, the results indicated that for the
average trauma population with a post-dose requirement of
8.7 units of RBC (population average), peak plasma levels of
rFVIIa activity equivalent to approximately 65 U.ml-1 (equal to
approximately 43 nM) may be expected. Moreover, the aver-
age level appeared to remain above 40 U.ml-1 (approximately
26 nM) for most of the four hours after the initial dose. In com-
parison with this, for subjects with an estimated post-dose
RBC transfusion requirement of 40 units, the predicted level
of coagulant activity displayed a significantly faster decline and
approached, but did not fall below, the profile for the hemo-
philia population (Figure 4).
Table 2
Population pharmacokinetic model parameter estimates (n = 230)
Variable Estimate (95% CI) Between patient CV
Clearance (ml.kg-1.h-1) 40 (37–44) 30%
Central compartment volume (ml.kg-1) 89 (60–132) 32%
Inter-compartmental clearance (ml.kg-1.h-1) 24 (8–76) NA
Peripheral compartment volume (ml.kg-1) 31 (13–74) NA
Baseline concentration (U.ml-1) 0.29 (0.27–0.31) 39%
∆Clearance/RBC 1.014 (1.003–1.0025) NA
Initial half-life (h) 0.6 (0.2–1.3) NA
Terminal half-life (h) 2.4 (1.8–5.5) NA
The within-patient variability (random error) was estimated to be 32%. ∆Clearance/RBC is the change in clearance per unit of red blood cells 
based on the model-specified potency function. CI, confidence interval; CV, coefficient of variation; NA, not applicable.
Figure 3
Population factor VII (FVII) coagulant activity profile modeled from the study dosing regimen
study dosing regimen. Dots represent the observed FVII coagulant 
activities from both frequent and sparse sampling while the solid line is 
trauma average population profile for multiple dosing. This model 
shows dosing in an adult hemophilia population superimposed for com-
parison (see Materials and methods).
Figure 4
Population pharmacokinetics profiles simulated at various red blood cell (RBC) transfusion requirements (20, 30, and 40 unit after dosing) – increasi g transfusio  requirement linked with increasing clearance
cell (RBC) transfusion requirements (20, 30, and 40 units after dosing) 
– increasing transfusion requirement linked with increasing clearance. 
The full line depicts the global trauma population (Trauma, mean of 8.7 
RBC units) Data for a hemophilia population has been superimposed 
for comparison(see Materials and methods).Page 6 of 10
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Available online http://ccforum.com/content/10/4/R104The variation in FVIIa coagulant activity in the trauma popula-
tion was considerable. Part of this variation was attributable to
differences in RBC transfusion requirement, resulting in signif-
icantly different predicted pharmacokinetic profiles depending
on this covariate. As reflected in the data (Figure 3) and the
population pharmacokinetic model parameters (Table 2), the
remaining variation not accounted for was still considerable;
however, with the dosing schedule used in this study, it
appears that even trauma subjects with high distribution vol-
umes and clearance (compared with population average) will
achieve plasma levels of rFVIIa activity that do not fall below
levels seen in the hemophilia populations managed with a sin-
gle dose of 90 µg.kg -1.
Discussion
In this large prospective study evaluating the pharmacokinetic
properties of rFVIIa in trauma patients with severe bleeding,
we mainly observed that: the mean clearance was 40 ml.kg-1.h-
1 and the terminal half-life 2.4 hours; a high intra- and inter-
patient variability was noted in the volume of distribution and
clearance; and this high variability was significantly correlated
with the transfusion requirements and thus blood loss. The
pharmacokinetic analyses reported here complete our previ-
ous report on the clinical efficacy and safety data, which sug-
gested that, in severe blunt trauma patients, a dosing schedule
for rFVIIa of 200 µg.kg-1 followed one and three hours later by
additional doses of 100 µg.kg-1 in patients with severe bleed-
ing is an effective hemostatic therapy [10].
Although definite conclusions could not be drawn from the
non-compartmental pharmacokinetic analysis due to the small
number of patients analyzed, profiles derived using this
method of analysis were valuable in giving an essentially
model-free interpretation to the population data. The observed
variability in the results of Cmax was expected, due the variation
in distribution volume and clearance. The mean clearance of
approximately 40 ml.kg-1.h-1 noted in the non-compartmental
analysis was almost identical to that seen in the population
pharmacokinetics analysis. Pharmacokinetic population mode-
ling and analysis was successful in describing the profile of
rFVIIa pharmacokinetics in trauma patients, in terms of a two-
compartment model. For a few parameters in the model (inter-
compartmental clearance and peripheral compartment vol-
ume), inter-subjects variation was not estimated. Moreover,
the precision of the corresponding population mean parame-
ter estimates was relatively low, compared with the other
parameters in the model. However, considering the amount
and quality of the data available, this was not unexpected and
was considered satisfactory.
The estimated population pharmacokinetics profile at a post-
dose RBC requirement of 8.7 units (the population average)
indicated that, after three doses of rFVIIa, the peak plasma FVII
coagulant activity of the population pharmacokinetics profile
was approximately 65 U.ml-1 (43 nM). Furthermore, the plasma
level appeared to remain above 40 U.ml-1 (approximately 26
nM) for most of the time over the four hours after the initial
dose (Figure 3). The pharmacokinetic modeling and analysis
as described here highlight that the trauma population consti-
tute a group of patients with very high intra- and inter-patient
variation in terms of rFVIIa kinetics. This may well reflect more
than just differences in RBC transfusion requirements and
underline the difficulties in attempting to treat such a diverse
group of patients using a one-regimen-for-all approach to
treatment. The population pharmacokinetic analysis illustrates
the variation between trauma patients in terms of the rFVIIa
pharmacokinetics, a variation that, in turn, has an effect on
which dose will be required for obtaining and maintaining an
effective FVII coagulant activity. Our analyses suggest that the
chosen dose regimen will yield adequate plasma FVII coagu-
lant activity during the crucial treatment period even when vol-
ume of distribution and plasma clearance are elevated.
The population model describing the study population as a
whole was appropriate for individual patients and helped iden-
tify covariates that could explain some of the pharmacokinetic
variability noted in this trauma population. In spite of this high
variation, a significant correlation was found, in that clearance
of rFVIIa was found to increase with increasing RBC require-
ment (Figure 2), most likely due to bleeding and plasma vol-
Table 3
Estimates of population average clearance and terminal half-life at various post-dose red blood cell requirements
Population RBC requirements (Units) Estimated clearance (ml.kg-1.h-1) Terminal half-life (h)
Hemophiliaa NA 29 4.4
Trauma 0 36 2.6
8.7b 40 2.4
20 47 2.1
30 54 1.9
40 62 1.7
aObtained in patients with hemophilia (see Materials and methods). bThis value corresponds to the trauma population average. NA, not applicable; 
RBC, red blood cell.Page 7 of 10
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dose RBC requirement, the estimated clearance of rFVIIa
would be 36 ml.kg-1.h-1 and the terminal half-life would be 2.6
hours. These estimates are in good agreement with non-com-
partment and population analysis results reported in (non-
bleeding) healthy volunteers [20,21]. However with an RBC
requirement of 40 units, clearance almost doubles to 62 ml.kg-
1.h-1 while the half life is shortened by nearly one hour to 1.7
hours. When population pharmacokinetic profiles were simu-
lated at various post-dose RBC requirements, it was found
that an increase in RBC requirement correlated with a more
rapid decrease in the predicted FVII coagulant activity. Fur-
thermore, predicted peak plasma activities after second and
third doses of rFVIIa were reduced as RBC requirements
increased, and overall exposure to rFVIIa – as assessed by
area under the FVII coagulant activity-time profile – was also
reduced. These results are not surprising since hemorrhage is
well known to markedly modify pharmacokinetic parameters
[22,23]. Although not based on baseline information – since
the RBC is measured after the first dose of rFVIIa – this corre-
lation reflects a clinically relevant interplay between the meas-
ured FVII coagulant activity and the RBC transfusion volume
and may help clinicians in choosing an appropriate dose
according to the clinically estimated blood loss and/or bleed-
ing rate. Therefore, our pharmacokinetic model may help to tar-
get appropriate rFVIIa concentrations in future randomized
trials in other clinical conditions, such as postoperative bleed-
ing [24,25]. Based on simulations using various post-dose
RBC transfusion requirements and the observed individual lev-
els of FVIIa coagulant activity in the study, it can, however, be
anticipated that with the dosing schedule employed in this
study, even patients with high distribution volumes and/or high
RBC transfusion requirements due to severe bleeding will
achieve a FVII coagulant activity at least equal to that known to
be clinically effective in hemophilia settings.
Clinical studies with rFVIIa have not identified pharmacody-
namic markers that reliably predict the in vivo hemostatic
effect of rFVIIa; thus, measures such as prothrombin time and
activated partial thromboplastin time are poor indicators of
bleeding control in the coagulopathic patient [8]. It is impor-
tant, therefore, to establish, from existing clinical data derived
from trauma cohorts, that the total dose and dosing schedules
for rFVIIa as evaluated in controlled studies are effective in
achieving a pharmacokinetic profile of plasma FVII coagulant
activity that supports the observed clinical efficacy of this
hemostatic agent in trauma patients. The analysis presented
here reveals some important aspects of the pharmacokinetics
in this population, in terms of how variable it is and which fac-
tors may help in explaining some of this variation. But it also
demonstrates that the dosing regimen chosen leads to FVIIa
coagulant activity levels known to be efficient in the hemophilia
population, for most subjects in the population, even those
with above-average volumes of distribution and plasma clear-
ance. This result is important since considerable variation in
the range of doses of rFVIIa (from 40 to 300 µg.kg-1) has been
noted in previously reported case series in trauma [7,8,26,27].
Some limitations in our study deserve consideration. First, only
one dosing schedule for rFVIIa was studied and the question
remains of whether the same level of efficacy could be
achieved with lower total doses or a different regimen of rFVIIa
dosing [10]. The pharmacokinetic analysis described here is
obviously limited by this fact; but it does demonstrate that a
satisfactorily high level of FVII coagulant activity is obtained
with the chosen regimen, compared with the levels seen in the
hemophilia population, when managed with 90 µg/kg. There-
fore, based on the results of the pharmacokinetic analysis
described in this study, and the safety and efficacy outcomes
as described by Boffard and colleagues [10], a phase III multi-
center randomized placebo-controlled clinical trial investigat-
ing rFVIIa in severely injured trauma patients with bleeding
refractory to standard treatment is currently ongoing with
exactly the same dosing regimen as described here (that is to
say, 200 + 100 + 100 µg.kg-1 at hours 0, 1, and 3, respec-
tively), in order to achieve appropriate levels of rFVIIa in the
study population.
Second, there are no clear data concerning the optimal dura-
tion of adequate rFVIIa concentrations required in bleeding
trauma patients. This concept is difficult to test in the context
of a multi-center randomized placebo-controlled clinical trial,
as the clinician decision that 'bleeding has stopped' is likely to
be highly subjective. In the case series of 81 patients
described by Dutton and colleagues [8], among the 46 sub-
jects with acute hemorrhagic coagulopathy, doses of rFVIIa
employed ranged from 48 to 148 µg.kg-1 and patients in the
series received an average of 1.2 (range 1 to 3) doses of
rFVIIa. However, it should also be emphasized that, in this
series, 25% of patients did not adequately respond to rFVIIa
administration [8]. Therefore, the need for re-injection in
selected patients remains a matter of debate in trauma
patients and may ultimately depend on whether bleeding con-
trol has been achieved in a given patient.
Third, the average concentration targeted in our study (>40
U.mL-1) was based on in vitro studies and clinical studies con-
ducted in hemophilic patients. Further evidence is required to
confirm this average target concentration in severely bleeding
patients. Nevertheless, it is notable that the only available ran-
domized study that proved the efficacy of rFVIIa in trauma
patients targeted this concentration [10].
Fourth, a larger amount of data would have enabled a more
precise estimation of the model parameters and possibly also
inclusion of intra-subject variance on all primary parameters.
Lastly, pharmacokinetic models usually assume the volume
and rate constants remain fixed for the duration of the experi-
ments and, in our study, we modeled rFVIIa in a non-stationary
system. We have tried to account for this by including RBCPage 8 of 10
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Available online http://ccforum.com/content/10/4/R104transfusion requirement as a covariate. However, the variability
inherent in this clinical setting probably still adds to the intra-
and inter-patient variabilities [28].
Conclusion
In trauma patients with severe bleeding, the mean clearance of
rFVIIa was 40 ml.kg-1.h-1 and its terminal half-life 2.4 hours. A
high intra- and inter-patient variability was observed in the vol-
ume of distribution and clearance of rFVIIa, mainly related with
the transfusion requirements. This pharmacokinetic analysis
completes our previous report on the clinical efficacy and
safety of rFVIIa in trauma patients with severe bleeding [10]
and may help to determine the precise, appropriate dosing
regimen in future trials and clinical practice. Our study sug-
gests that dosing might be adapted to the clinically estimated
blood loss and/or bleeding rate.
Competing interests
KB, SR, YK, and BR have received consultancy fees and lec-
ture sponsorships from Novo Nordisk. RR has received lecture
sponsorship from Novo Nordisk. TK and RTyP are employed
by Novo Nordisk A/S.
Authors' contributions
TK and RTyP designed and performed the pharmacokinetic
analyses. TK, RTyP, and BR drafted the manuscript. All
authors participated in the design and coordination of the
study, and read and approved the final manuscript.
Acknowledgements
The trial was funded by Novo Nordisk A/S, Bagsvaerd, Denmark. We 
wish to thank Henrik F Thomsen (Department of Biostatistics, Novo Nor-
disk A/S, Copenhagen, Denmark) for assistance in interpreting the data. 
We are indebted to the patients, trial coordinators, and nurses and phy-
sicians who participated in this trial.
References
1. Abshire T, Kenet G: Recombinant factor VIIa: review of efficacy,
dosing regimens and safety in patients with congenital and
acquired factor VIII or IX inhibitors.  J Thromb Haemost 2004,
2:899-909.
2. Hoffman M, Monroe DM: A cell-based model of haemostasis.
Thromb Haemost 2001, 85:958-965.
3. Monroe DM, Hoffman M, Oliver JA, Roberts HR: Platelet activity
of high dose factor VIIa is independent of tissue factor.  Br J
Haematol 1997, 99:542-547.
4. Carr ME, Martin EJ: Recombinant factor VIIa: clinical applica-
tions for an intravenous haemostatic agent with broad-spec-
trum potential.  Expert Rev Cardiovasc Ther 2004, 2:661-674.
5. Roberts HR, Monroe DM, Escobar MA: Current concepts of
hemostasis: implications for therapy.  Anesthesiology 2004,
100:885-893.
6. Malherbe S, Tsui BC, Stobart K, Koller J: Argatroban as antico-
agulant in cardiopulmonary bypass in an infant and attempted
reversal with recombinant activated factor VII.  Anesthesiology
2004, 101:1048-1049.
7. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev
J, Lynn M: Recombinant activated factor VII for adjunctive hem-
orrhage control in trauma.  J Trauma 2001, 51:431-439.
8. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor JO, Hess
JR, Scalea TM: Factor VIIa for correction of traumatic coagulop-
athy.  J Trauma 2004, 57:709-719.
9. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui
D, Anthuber M, Mirza DF, Juhlman L, Bechstein WO, et al.:
Recombinant coagulation factor VIIa in major liver resection: a
randomized, placebo-controlled, double blind clinical trial.
Anesthesiology 2005, 102:269-275.
10. Boffard KD, Riou B, Warren B, Iau P, Rizoli S, Kluger Y, Rossaint
R, Axelsen M, The NovoSeven® Trauma Study Group: Recom-
binant Factor VIIa as adjunctive therapy for bleeding control in
severely injured trauma patients. A randomized, placebo-con-
trolled, double-blind clinical trial.  J Trauma 2005, 59:8-18.
11. Allen GA, Monroe III, Roberts HR, Hoffman M: The effect of factor
X level on thrombin generation and the procoagulant effect of
activated factor VII in a cell-based model of coagulation.  Blood
Coagul Fibrinolysis 2000, 11(Suppl 1):S3-S7.
12. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA,
Gringeri A: Relationship between factor VII activity and clinical
efficacy of recombinant factor VIIa given by continuous infu-
sion in patients with factor VIII inhibitors.  Thromb Haemost
2001, 86:954-958.
13. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thom-
sen HF, Erhardsten E, Giangrande PC: Pharmacokinetics of acti-
vated recombinant coagulation factor VII (NovoSeven) in
children vs adults with haemophilia A.  Haemophilia 2004,
10:352-359.
14. Erhardtsen E: Pharmacokinetics of recombinant activated fac-
tor VII (rFVIIa).  Semin Thromb Hemost 2000, 26:385-391.
15. Morrissey JH, Macik BG, Neunenschwander PF, Comp PC: Quan-
tification of activated FVII levels in plasma using a tissue factor
mutant selectively deficient in promoting factor VII activation.
Blood 1993, 81:734-744.
16. Aarons L: Population pharmacokinetics: Theory and practice.
Br J Clin Pharmacol 1991, 32:669-670.
17. Ette EI, Williams PJ: Population pharmacokinetics. I: Back-
ground, concepts, and models.  Ann Pharmacother 2004,
38:1702-1706.
18. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-
Cox K, Birch K, Glazer S, Roberts HR: Pharmacokinetics and
pharmacodynamics of recombinant factor VIIa.  Clin Pharmacol
Ther 1994, 55:638-648.
19. The NONMEM Project Group: NONMEM Users Guide, Novem-
ber 1994, Part V: Introductory Guide San Francisco; University of
California. 
20. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E: A study of the
pharmacokinetics and safety of recombinant activated factor
VII in healthy Caucasian and Japanese subjects.  Blood Coagul
Fibrinolysis 2005, 16:259-266.
21. Girard P, Nony P, Erhardtsen E, Delair F, French P, Dechavanne M,
Boissel JP: Population pharmacokinetics of recombinant factor
VIIa in volunteers anticoagulated with acenocoumarol.
Thromb Haemost 1998, 80:109-113.
22. Kurita T, Kazama T, Morita K, Fujii S, Uraoka M, Takata K, Sato S:
Influence of fluid infusion associated with high-volume blood
loss on plasma propofol concentrations.  Anesthesiology 2004,
100:871-878.
23. Johnson KB, Egan TD, Kern SE, McJames SW, Cluff ML, Pace NL:
Influence of hemorrhagic shock followed by crystalloid resus-
Key messages
• In trauma patients with severe bleeding, the mean clear-
ance of recombinant factor VIIa is 40 ml.kg-1.h-1 and its 
terminal half-life 2.4 hours.
• A high intra- and inter-patient variability occurs in the 
volume of distribution and clearance of recombinant 
factor FVIIa in trauma patients with severe bleeding.
• This high variability was mainly related to the transfusion 
requirements and thus the blood loss and/or bleeding 
rate
• Our study suggests that dosing might be adapted to 
the clinically estimated blood loss and/or bleeding rate 
in future trials and clinical practice.Page 9 of 10
(page number not for citation purposes)
Critical Care    Vol 10 No 4    Klitgaard et al.citation on propofol: pharmacokinetic and pharmacodynamic
analysis.  Anesthesiology 2004, 101:647-659.
24. Karkouti K, Beattie WS, Wijeysundera DN, Yau TM, McCluskey
SA, Ghannam M, Sutton D, van Rensburg A, Karski J: Recom-
binant factor VIIa for intractable blood loss after cardiac sur-
gery: a propensity score-matched case-control analysis.
Transfusion 2005, 45:26-34.
25. Weiskopf RB: Intraoperative use of recombinant activated
coagulation factor VII.  Anesthesiology 2002, 96:1287-1289.
26. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E: Possible
role of recombinant activated factor VII (rFVIIa) in the control
of hemorrhage associated with massive trauma.  Can J
Anaesth 2002, 49(Suppl):S15-S20.
27. Barletta JF, Ahrens CL, Tyburski JG, Wilson RF: A review of
recombinant factor VII for refractory bleeding in non-hemo-
philic trauma patients.  J Trauma 2005, 58:646-651.
28. Kurita T, Kazama T, Morita K, Fujii S, Uraoka M, Takata K, Sato S:
Influence of fluid infusion associated with high-volume blood
loss on plasma propofol concentrations.  Anesthesiology 2004,
100:871-878.Page 10 of 10
(page number not for citation purposes)
